Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove


A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published: July 25, 2022 doi: 10.3791/64213


The present protocol describes the bioengineering of outer membrane vesicles to be a "Plug-and-Display" vaccine platform, including production, purification, bioconjugation, and characterization.


Biomimetic nanoparticles obtained from bacteria or viruses have attracted substantial interest in vaccine research and development. Outer membrane vesicles (OMVs) are mainly secreted by gram-negative bacteria during average growth, with a nano-sized diameter and self-adjuvant activity, which may be ideal for vaccine delivery. OMVs have functioned as a multifaceted delivery system for proteins, nucleic acids, and small molecules. To take full advantage of the biological characteristics of OMVs, bioengineered Escherichia coli-derived OMVs were utilized as a carrier and SARS-CoV-2 receptor-binding domain (RBD) as an antigen to construct a "Plug-and-Display" vaccine platform. The SpyCatcher (SC) and SpyTag (ST) domains in Streptococcus pyogenes were applied to conjugate OMVs and RBD. The Cytolysin A (ClyA) gene was translated with the SC gene as a fusion protein after plasmid transfection, leaving a reactive site on the surface of the OMVs. After mixing RBD-ST in a conventional buffer system overnight, covalent binding was formed between the OMVs and RBD. Thus, a multivalent-displaying OMV vaccine was achieved. By replacing with diverse antigens, the OMVs vaccine platform can efficiently display a variety of heterogeneous antigens, thereby potentially rapidly preventing infectious disease epidemics. This protocol describes a precise method for constructing the OMV vaccine platform, including production, purification, bioconjugation, and characterization.


As a potential vaccine platform, outer membrane vesicles (OMVs) have attracted more and more attention in recent years1,2. OMVs, mainly secreted naturally by gram-negative bacteria3, are spherical nanoscale particles composed of a lipid bilayer, usually in the size of 20-300 nm4. OMVs contain various parental bacterial components, including bacterial antigens and pathogen-associated molecular patterns (PAMPs), which serve as solid immune potentiators5. Benefiting from their unique components, natural vesicle structure, and great genetic engineering modification sites, OMVs have been developed for use in many biomedical fields, including bacterial vaccines6, adjuvants7, cancer immunotherapy drugs8, drug delivery vectors9, and anti-bacterial adhesives10.

The SARS-CoV-2 pandemic, which has spread worldwide since 2020, has taken a heavy toll on global society. The receptor-binding domain (RBD) in spike protein (S protein) can bind with human angiotensin-converting enzyme 2 (ACE2), which then mediates the entry of the virus into the cell11,12,13. Thus, RBD seems to be a prime target for vaccine discovery14,15,16. However, monomeric RBD is poorly immunogenic, and its small molecular weight makes it difficult for the immune system to recognize, so adjuvants are often required17.

In order to increase the immunogenicity of RBD, OMVs displaying polyvalent RBDs were constructed. Existing studies using OMV to display RBD usually fuse RBD with OMV to be expressed in bacteria18. However, RBD is a virus-derived protein, and prokaryotic expression is likely to affect its activity. To solve this problem, the SpyTag (ST)/SpyCatcher (SC) system, derived from Streptococcus pyogenes, was used to form a covalent isopeptide with OMV and RBD in a conventional buffer system19. The SC domain was expressed with Cytolysin A (ClyA) as a fusion protein by bioengineered Escherichia coli, and ST was expressed with RBD via the HEK293F cellular expression system. OMV-SC and RBD-ST were mixed and incubated overnight. After purification by ultracentrifugation or size-exclusion chromatography (SEC), OMV-RBD was obtained.

Subscription Required. Please recommend JoVE to your librarian.


1. Plasmid construction

  1. Insert DNA encoding SpyCatcher sequence (Supplementary File 1) into an ampicillin-resistant pThioHisA-ClyA plasmid (see Table of Materials) between the BamH I and Sal I sites to construct the plasmid pThioHisA ClyA-SC following a previously published report20.
  2. Ligate the synthesized SpyTag-RBD-Histag fusion gene (Supplementary File 1) into a pcDNA3.1 plasmid (see Table of Materials) between the BamH I and EcoR I sites to construct the plasmid pcDNA3.1 RBD-ST following a previously published report19.

2. OMV-SC preparation

  1. Perform ClyA-SC transformation following the steps below.
    1. Add 5 µL of pThioHisA ClyA-SC plasmid solution (50 ng/µL) to 50 µL of BL21 competent strain, gently blow, and let cool on ice for 30 min.
    2. Place the solution for 90 s in the water bath at 42 °C, and then immediately put the mixed solution on ice for 3 min.
    3. Add 500 µL of LB medium to the bacterial suspension and, after mixing, culture at 220 rpm at 37 °C for 1 h.
    4. Plate all the transformation onto an LB agar plate containing ampicillin (100 µg/mL, see Table of Materials) and culture overnight at 37 °C.
      NOTE: In subsequent experiments, the ampicillin was kept at the same concentration in the medium. If not, this may cause loss of plasmids in the bacteria.
  2. For OMV-SC production, perform the steps below.
    1. Isolate a single colony from the plate (step 2.1.4.) to 20 mL of LB (ampicillin-resistant) medium and culture overnight at 220 rpm at 37 °C.
    2. Inoculate the bacterial solution (from step 2.2.1.) into 2 L medium, culture at 220 rpm, 37 °C for 5 h until the logarithmic growth stage (the OD600nm is between 0.6 to 0.8).
    3. When the OD at 600 nm of the bacterial solution reaches 0.6-0.8, add isopropyl beta-D-thiogalactopyranoside (IPTG, see Table of Materials) to make the final concentration of the bacterial solution to be 0.5 mM, and then culture overnight at 220 rpm at 25 °C.
  3. Perform OMV-SC purification.
    1. Centrifuge the bacterial solution at 7,000 x g at 4 °C for 30 min.
    2. Filter the supernatant with a 0.22 µm membrane filter, then concentrate it using a 100 kD ultrafiltration membrane or hollow fiber column (see Table of Materials).
    3. Filter the concentrate through a 0.22 µm membrane filter, then centrifuge it at 150,000 x g at 4 °C for 2 h using an ultracentrifuge (see Table of Materials), and discard the supernatant with a pipette.
    4. Resuspend the precipitation with PBS and store it at −80 °C. The solution can maintain long-term stability at −80 °C.

3. RBD-ST preparation

  1. Perform RBD-ST transfection following the steps below.
    1. Select an appropriate eukaryotic expression system (e.g., HEK293F) and culture the cells overnight at 130 rpm at 37 °C after recovery.
    2. Add 20 µL of HEK293F cell solution into the automated cell counter (see Table of Materials), record the number of cells, adjust the concentration to 1 x 106 cells/mL, and then culture the cells at 130 rpm at 37 °C for 4 h.
    3. Filter RBD-ST plasmid through a 0.22 µm membrane filter, and add 300 µg of plasmids into the cell culture medium (see Table of Materials) until the final volume is 10 mL; shake for 10 s.
    4. Heat PEI (1 mg/mL, see Table of Materials) to 65 °C in the water bath, mix 0.7 mL of PEI with 9.3 mL of cell culture medium, and shake intermittently for 10 s.
      NOTE: Do not shake the solution vigorously. Otherwise, the resulting bubbles may affect the transfection efficiency.
    5. Add plasmid solution to the PEI solution, shake the mixture intermittently for 10 s, and incubate it at 37 °C for 15 min.
    6. Add the mixture to 280 mL of cell culture medium and culture at 130 rpm at 37 °C for 5 days.
  2. Perform RBD-ST purification.
    1. Centrifuge the cells at 6,000 x g at 25 °C for 20 min and use a pipette to collect the supernatant.
    2. Fill the column with 2 mL of Ni-NTA agarose (see Table of Materials) and wash it 3x with 3x PBS.
    3. Add imidazole (see Table of Materials) into the cell supernatant to make the final concentration of 20 mM, and load the cell supernatant 2x.
    4. Add 3 column volumes (CV) of PBS containing 20 mM of imidazole for washing, and collect the washing fraction.
    5. Gradient elute with 3 CV of PBS containing low to high concentrations (e.g., 0.3 M, 0.4 M, 0.5 M) of imidazole; elute 2x for each concentration.
    6. Use SDS-PAGE21 to identify the RBD-ST in different concentration gradients.

4. OMV-RBD bioconjugation and purification

  1. Determine the protein concentration by the BCA method (see Table of Materials).
    1. Serially dilute the standard BSA protein solution from 2 mg/mL to 0.0625 mg/mL, dilute the purified OMV-SC and RBD-ST 10x, then mix BCA working solutions A and B (provided in the assay kit) at a ratio of 50:1 (v/v).
    2. Add diluted protein solution (25 µL/well) and mix with BCA working solution (200 µL/well); incubate at 37 °C for 30 min.
    3. Measure the absorbance (OD) at 562 nm of each well and calculate the protein concentration from the standard curve22.
  2. Perform bioconjugation of OMV-SC and RBD-ST following the steps below.
    1. Mix OMV-SC and RBD-ST in PBS at a 40:1 (w/w) ratio.
    2. Vertically rotate to blend the mixture overnight at 15 rpm at 4 °C.
      NOTE: Different antigens may react in different proportions. One could try different reaction ratios based on the characteristics of the antigen.
  3. Verify the reaction efficiency.
    1. Prepare 10 µL of OMV-SC, RBD-ST, and the reaction product (step 4.2.). Add 2.5 µL of 5x loading buffer (see Table of Materials), and heat the samples at 100 °C for 5 min. Load the samples into the gel (10 µL/well). Perform electrophoresis at 60 V for 20 min and change the condition to 120 V for 1 h.
    2. Transfer the protein from the gel to PVDF western blotting membranes (see Table of Materials) at 100 V for 70 min.
    3. Put the membrane into 5% non-fat powdered milk/TBST and shake for 1 h. Then, wash 3x with TBST for 5 min per wash with shaking.
    4. Put the membrane into 0.1% His-Tag antibody/TBST (see Table of Materials) and shake for 1 h, then wash 3x with TBST for 5 min per wash with shaking.
    5. Put the membrane into 0.02% anti-mouse IgG1 antibody (HRP)/TBST (see Table of Materials) and shake for 40 min, then wash 3x with TBST for 5 min per wash with shaking.
    6. Add enhanced chemiluminescence solution (see Table of Materials) and expose the membrane.
  4. Perform purification of OMV-RBD.
    1. Dilute 1 mL of reacted OMV-RBD solution to 10 mL, and centrifuge the dilution at 150,000 x g at 4 °C for 2 h.
    2. Use a pipette to discard the supernatant and suspend the residue with 10 mL of PBS. Centrifuge the suspension at 150,000 x g at 4 °C for 2 h.
    3. Discard the supernatant and suspend the residue with 1 mL of PBS.
      ​NOTE: If the solubility of the antigen is much lower, the same separation effect can be achieved by size-exclusion chromatography19.

5. Characterization

  1. Perform dynamic light scattering (DLS).
    1. Dilute the samples to a 100 µg/mL concentration and add 1 mL of sample into the sample cell.
    2. Choose "Size" for "Measurement type", "Protein" for "Sample material", "Water" for "Dispersant", "25 °C" for "Temperature", and then load samples and measure automatically23.
  2. Capture images using transmission electron microscopy (TEM).
    1. Dilute the samples to 100 µg/mL. Take a 200-mesh copper grid, add 20 µL of sample to it, and allow it to get absorbed for 10 min.
    2. Use filter paper to wick off the solution, add 20 µL of 3% uranyl acetate to the support film, and stain for 30 s.
    3. Wick off the uranyl acetate and dry the film naturally at room temperature for 1 h.
    4. Load the samples to the TEM system (see Table of Materials) and capture images at 80 kV.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

The flowchart for this protocol is shown in Figure 1. This protocol could be a general approach to utilizing OMVs as a vaccine platform; one only needs to choose the appropriate expression systems based on the type of antigens.

Figure 2 provides a feasible plasmid design scheme. The SC gene is connected with the ClyA gene via a flexible linker, while ST connects to the 5' terminal of the RBD gene with a His-tag gene for purification and verification. Western blot showed that the reaction gradually completes with increasing OMV-SC (Figure 3A). After ultracentrifugation, almost all of the unreacted RBD-ST remained in the supernatant. The second ultracentrifugation did not provide a further significant advantage over the first time (Figure 3B).

The distribution of particle size was determined by DLS (Figure 4). The Z-average hydrodynamic diameter of OMV-SC was 133 nm, while it was 152.6 nm for OMV-RBD (Table 1). These differences may be because RBD increases OMV particle size after intensive displaying. The results of TEM (Figure 5) are consistent with the DLS results. The images showed that the OMVs always have a standard spherical structure, whether connected to RBD or not. This indicates that the extraction, reaction, and purification conditions are conducive to maintaining the biological activity of OMVs.

Figure 1
Figure 1: Flowchart of OMV-RBD preparation. The ClyA-SC plasmid was transformed into E.coli, while the RBD-ST plasmid was transfected into HEK293F cells. After a period of culturing, OMV-SC and RBD-ST were isolated and purified. After bioconjugation in conventional buffer and ultracentrifugation, OMV-RBD was obtained. Please click here to view a larger version of this figure.

Figure 2
Figure 2: The plasmid profiles used in this study. (A) pThioHisA ClyA-SC plasmid. (B)pcDNA RBD-ST plasmid. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Verification of OMV-RBD by western blot. (A) The exploration of the reaction ratio between OMV-SC and RBD-ST with anti-6x HisTag. M: molecular weight marker 1: OMV-SC; 2: RBD-ST; 3: OMV:RBD = 10:1 (w/w); 4: OMV:RBD = 20:1; 5: OMV:RBD = 40:1. (B) Validation of the efficiency of ultracentrifugation with anti-6x HisTag. M: molecular weight marker 1: OMV-SC; 2: OMV-RBD pre-ultracentrifugation; 3: RBD-ST; 4: supernatant post first ultracentrifugation; 5: precipitate post first ultracentrifugation; 6: supernatant post second ultracentrifugation; 7: precipitate post second ultracentrifugation. Please click here to view a larger version of this figure.

Figure 4
Figure 4: Particle size distribution measured by DLS. (A) OMV-SC. (B) OMV-RBD. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Visualization of OMVs by TEM. (A) OMV-SC (200 µg/mL). (B) OMV-RBD (200 µg/mL). Please click here to view a larger version of this figure.

Sample Name Temperature (°C) Z-Ave (d.nm) PdI
OMV-SC 25 133 0.483
OMV-RBD 24.9 152.6 0.569

Table 1: Parameters measured by DLS.

Supplementary File 1: Plasmid sequences used in the present study. Please click here to download this File.

Subscription Required. Please recommend JoVE to your librarian.


To create a "Plug-and-Display" nanoparticle vaccine platform, SC-fused ClyA was expressed in BL21(DE3) strains, which is one of the most widely used models for recombinant protein production because of its advantages in protein expression24, so that there would be enough SC fragment displaying on the surface of the OMVs during the process of bacteria proliferation. At the same time, an ST-fused target antigen was prepared for the chemical coupling between the antigens and OMVs. This experimental scheme's advantages and future application prospects are mainly reflected in three aspects. First, the "Plug-and-Display" system of different antigens and biological nanoparticles is realized. The reaction and purification process could be fast and straightforward, which has significant advantages in developing vaccines for emergent infectious diseases and other scenarios. Second, it achieves the goal of high-density antigen displaying and provides a vaccine design method for some antigens with low immunogenicity. Third, the individual expression of OMVs and RBD (antigenic protein) is beneficial to ensure high antigen activity because conventional prokaryotic expression systems lack functions such as particular cofactors, molecular chaperones, and post-translational modifications, which may lead to protein loss and misfolding.

In the process of plasmid construction, the ClyA was chosen as a target to connect with SC mainly due to the loose barrel-shaped structure of the C-terminal of ClyA. Studies have shown that the hemoglobin protease (Hbp) autotransporter can display antigens from Streptococcus pneumonia and Mycobacterium tuberculosis25,26. Otherwise, if the antigen to be displayed is from a prokaryote, it is possible to construct the antigens directly into the C-terminal of ClyA without using SC/ST conjugation. This method may result in OMVs with higher displaying density, but there is still a risk that the antigenic proteins will not fold correctly. It is important to note that a flexible linker needs to be designed and used when SC/ST is inserted into the target fragment, which helps to improve the reaction efficiency between SC and ST. The linker sequence used here was GSGGSGGSGTG, and other flexible linkers can also be selected.

In addition to the SC/ST system for click-chemistry conjugation, Snooptag/Snoopcatcher and Sortase A conjugation are also commonly used for covalent conjugation between proteins27,28. At the same time, it has also been reported that the introduction of multiple different linkage systems on the same vector29 or the use of the same linkage system for multiple antigens19 can achieve the purpose of displaying multiple heterologous antigens on the same vector, and then polyvalent or multifunctional vaccines can be prepared.

High cytotoxicity and low yield limit the widespread use of OMVs as vaccine platforms4,30. Some LPS-related genes have been knocked out in the strain used in this protocol, according to relevant literature31,32,33, in order to reduce the cytotoxicity of OMVs. 1.18 mg of OMVs can be extracted from each 1 L of the bacterial solution by the method introduced in this protocol. The yield is still lower than that of some genetically modified high-vesicle-producing strains34. If necessary, high-pressure homogenization can also promote the germination of the bacterial membrane to produce more OMVs, which can achieve improved yield and displaying density at the same time35.

The induction conditions are crucial for the density of SC displayed on the surface of the OMVs. We monitored the expression of the target protein through SDS-PAGE and then screened out the induction condition, which is relatively mild and expresses more protein. Different proteins may require different induction conditions, and changes in the induction conditions may lead to differences in the density of SC displayed on the surface of the OMVs. Adjusting the antigen and carrier ratio after the experimental conditions change to explore the most appropriate reaction ratio is suggested. In addition, the purification of OMV-RBD can be achieved by SEM or ultracentrifugation. Both methods were tried; ultracentrifugation is more convenient, and the resulting OMV had a purity similar to the SEM protocol.

Subscription Required. Please recommend JoVE to your librarian.


The authors have nothing to disclose.


This work was supported by the Key Program of Chongqing Natural Science Foundation (No. cstc2020jcyj-zdxmX0027) and the Chinese National Natural Science Foundation Project (No. 31670936, 82041045).


Name Company Catalog Number Comments
Ampicillin sodium Sangon Biotech A610028
Automated cell counter Countstar BioTech
BCA protein quantification Kit cwbio cw0014s
ChemiDoc Touching Imaging System Bio-rad
Danamic Light Scattering Malvern Zetasizer Nano S90
Electrophoresis apparatus Cavoy Power BV
EZ-Buffers H 10X TBST Buffer Sangon Biotech C520009
Goat pAb to mouse IgG1 Abcam ab97240
High speed freezing centrifuge Bioridge H2500R
His-Tag mouse mAb Cell signaling technology 2366s
Imidazole Sangon Biotech A600277
Isopropyl beta-D-thiogalactopyranoside Sangon Biotech A600118
Ni-NTA His-Bind Superflow Qiagen 70691
Non-fat powdered milk Sangon Biotech A600669
OPM-293 cell culture medium Opm biosciences 81075-001
pcDNA3.1 RBD-ST plasmid Wuhan genecreat biological techenology
Phosphate buffer saline ZSGB-bio ZLI-9061
Polyethylenimine Linear Polysciences 23966-1
Prestained protein ladder Thermo 26616
pThioHisA ClyA-SC plasmid Wuhan genecreat biological techenology
PVDF Western Blotting Membranes Roche 03010040001
Quixstand benchtop systems (100 kD hollow fiber column) GE healthcare
SDS-PAGE loading buffer (5x) Beyotime P0015
Sodium chloride Sangon Biotech A100241
Supersignal west pico PLUS (enhanced chemiluminescence solution) Thermo 34577
Suspension instrument Life Technology Hula Mixer
Transmission Electron Microscope Hitachi HT7800
Tryptone Oxoid LP0042B
Ultracentrifuge Beckman coulter XPN-100
Ultraviolet spectrophotometer Hitachi U-3900
Yeast extract Sangon Biotech A610961



  1. Li, M., et al. Bacterial outer membrane vesicles as a platform for biomedical applications: An update. Journal of Controlled Release. 323, 253-268 (2020).
  2. Micoli, F., MacLennan, C. A. Outer membrane vesicle vaccines. Seminars in Immunology. 50, 101433 (2020).
  3. Toyofuku, M., Nomura, N., Eberl, L. Types and origins of bacterial membrane vesicles. Nature Reviews Microbiology. 17 (1), 13-24 (2019).
  4. Sartorio, M. G., Pardue, E. J., Feldman, M. F., Haurat, M. F. Bacterial outer membrane vesicles: From discovery to applications. Annual Review of Microbiology. 75, 609-630 (2021).
  5. Kaparakis-Liaskos, M., Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. Nature Reviews Immunology. 15 (6), 375-387 (2015).
  6. Petousis-Harris, H., Radcliff, F. J. Exploitation of Neisseria meningitidis group B OMV vaccines against N-gonorrhoeae to inform the development and deployment of effective gonorrhea vaccines. Frontiers in Immunology. 10, 683 (2019).
  7. Gnopo, Y. M. D., Watkins, H. C., Stevenson, T. C., DeLisa, M. P., Putnam, D. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery. Advanced Drug Delivery Reviews. 114, 132-142 (2017).
  8. Zhang, Y. X., Fang, Z. Y., Li, R. Z., Huang, X. T., Liu, Q. Design of outer membrane vesicles as cancer vaccines: A new toolkit for cancer therapy. Cancers. 11 (9), 1314 (2019).
  9. Berleman, J., Auer, M. The role of bacterial outer membrane vesicles for intra- and interspecies delivery. Environmental Microbiology. 15 (2), 347-354 (2013).
  10. Huang, W. L., Meng, L. X., Chen, Y., Dong, Z. Q., Peng, Q. Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy. Acta Biomaterialia. 140, 102-115 (2022).
  11. Hoffmann, M., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181 (2), 271-280 (2020).
  12. Robbiani, D. F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 584 (7821), 437-442 (2020).
  13. Wang, M. Y., et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in Cellular and Infection Microbiology. 10, 587269 (2020).
  14. Yang, S., et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Disease. 21 (8), 1107-1119 (2021).
  15. Wang, Z., et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 592 (7855), 616-622 (2021).
  16. Amanat, F., et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 184 (15), 3936-3948 (2021).
  17. Tan, H. X., et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communication. 12 (1), 1403 (2021).
  18. Thapa, H. B., Mueller, A. M., Camilli, A., Schild, S. An intranasal vaccine based on outer membrane vesicles against SARS-CoV-2. Frontiers in Microbiology. 12, 752739 (2021).
  19. Ma, X., et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity. 53 (6), 1315-1330 (2020).
  20. Yang, Z., et al. RBD-modified bacterial vesicles elicited potential protective immunity against SARS-CoV-2. Nano Letters. 21 (14), 5920-5930 (2021).
  21. Rhinesmith, T., Killinger, B. A., Sharma, A., Moszczynska, A. Multimer-PAGE: A method for capturing and resolving protein complexes in biological samples. Journal of Visualized Experiments. (123), e55341 (2017).
  22. Arslan, A., et al. Determining total protein and bioactive protein concentrations in bovine colostrum. Journal of Visualized Experiments. (178), e63001 (2021).
  23. Alves, N. J., Turner, K. B., Walper, S. A. Directed protein packaging within outer membrane vesicles from Escherichia coli: Design, production and purification. Journal of Visualized Experiments. (117), e54458 (2016).
  24. Kim, S., et al. Genomic and transcriptomic landscape of Escherichia coli BL21(DE3). Nucleic Acids Research. 45 (9), 5285-5293 (2017).
  25. Daleke-Schermerhorn, M. H., et al. Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach. Applied and Environmental Microbiology. 80 (18), 5854-5865 (2014).
  26. Kuipers, K., et al. Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. Vaccine. 33 (17), 2022-2029 (2015).
  27. Veggiani, G., et al. Programmable polyproteams built using twin peptide superglues. Proceedings of the National Academy of Sciences of the United States of America. 113 (5), 1202-1207 (2016).
  28. Saunders, K. O., et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 594, 553-559 (2021).
  29. van Saparoea, H. B. V., Houben, D., Kuijl, C., Luirink, J., Jong, W. S. P. Combining protein ligation systems to expand the functionality of semi-synthetic outer membrane vesicle nanoparticles. Frontiers in Microbiology. 11, 890 (2020).
  30. Needham, B. D., et al. Modulating the innate immune response by combinatorial engineering of endotoxin. Proceedings of the National Academy of Sciences of the United States of America. 110 (4), 1464-1469 (2013).
  31. Zanella, I., et al. Proteome-minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform. Journal of Extracellular Vesicles. 10 (4), 12066 (2021).
  32. Wang, J. L., et al. Truncating the structure of lipopolysaccharide in Escherichia coli can effectively improve poly-3-hydroxybutyrate production. ACS Synthetic Biology. 9 (5), 1201-1215 (2020).
  33. Liu, Q., et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Scientific Reports. 6, 34776 (2016).
  34. Balhuizen, M. D., Veldhuizen, E. J. A., Haagsman, H. P. Outer membrane vesicle induction and isolation for vaccine development. Frontiers in Microbiology. 12, 629090 (2021).
  35. Hua, L., et al. A novel immunomodulator delivery platform based on bacterial biomimetic vesicles for enhanced antitumor immunity. Advanced Materials. 33 (43), 2103923 (2021).
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Play Video

Cite this Article

Feng, R., Li, G. C., Jing, H. M., Liu, C., Xue, R. Y., Zou, Q. M., Li, H. B. A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain. J. Vis. Exp. (185), e64213, doi:10.3791/64213 (2022).More

Feng, R., Li, G. C., Jing, H. M., Liu, C., Xue, R. Y., Zou, Q. M., Li, H. B. A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain. J. Vis. Exp. (185), e64213, doi:10.3791/64213 (2022).

Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter